Cinda Biotech declares that the first domestic SIRPα antibody CD47 pathway has deployed 3 new drugs

Author: Plus One

On September 8, Cinda Biotech declared a new type of anti-SIRP-alpha antibody IBI397 (Alector R&D code: AL008)

From: CDE official website

Dual mechanism inhibition of SIRPα/CD47 pathway

IBI397 is the first SIRP-alpha inhibitor with a unique dual mechanism and a differentiated mechanism

IBI397 single agent inhibited tumor growth and enhanced the activity of M1 macrophages in preclinical humanized mouse tumor models

At the same time, in pre-clinical studies, there was no side effect of clearing red blood cells or platelets

At present, this product has not started clinical practice at home and abroad

CD47-SIRPα: The Way of Kings

In the development of new anti-cancer drugs, the CD47-SIRPα pathway has attracted much attention

In March 2020, Gilead announced that it had acquired FortySeven Biotech, a company that focuses on the development of CD47 pathway inhibitors, for a total value of US$4.

With the blessing of Dachang, this field in China is also a red sea

Domestic CD47 antibody drug development pattern (Insight)

Cinda has already deployed 3 products for CD47-SIRPα, including CD47 monoclonal antibody IBI188 (letaplimab) and PD-L1/CD47 double antibody IBI322.

IBI188 project timeline

From: Insight database (http://db.